ABL-001 | B1949

ABL-001 is a potent allosteric inhibitor of BCR-ABL. ABL001 binds to the myristoyl pocket of ABL1 and induces the formation of an inactive kinase conformation. ABL001 prevents emergence of resistant disease when administered in combination with nilotinib in an in vivo murine model of CML (chronic myeloid leukemia).

ABL-001 is a potent allosteric inhibitor of BCR-ABL. ABL001 binds to the myristoyl pocket of ABL1 and induces the formation of an inactive kinase conformation. ABL001 prevents emergence of resistant disease when administered in combination with nilotinib in an in vivo murine model of CML (chronic myeloid leukemia).

B1949 | ABL-001 DataSheet

Alternate Name/Synonyms: (R)-N-(4-(chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-5-yl)nicotinamide; Asciminib

Appearance: Crystalline solid

Formulation: N/A

CAS Number: 1492952-76-7

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₂₀H₁₈ClF₂N₅O₃

Molecular Weight: 449.84

Cell-Permeable?: Yes

Purity: ≥98% by HPLC

Solubilities: DMSO

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A potent allosteric inhibitor of BCR-ABL

MDL Number: N/A

PubChem CID: 72165228

SMILES: C1CN(CC1O)C2=NC=C(C=C2C3=CC=NN3)C(=O)NC4=CC=C(C=C4)OC(F)(F)Cl

InChi: InChI=1S/C20H18ClF2N5O3/c21-20(22,23)31-15-3-1-13(2-4-15)26-19(30)12-9-16(17-5-7-25-27-17)18(24-10-12)28-8-6-14(29)11-28/h1-5,7,9-10,14,29H,6,8,11H2,(H,25,27)(H,26,30)/t14-/m1/s1

InChi Key: VOVZXURTCKPRDQ-CQSZACIVSA-N